GlassScriptPhysician profile
Gretta Fridman
NPI 1699964726
$6,942.90
in general payments reported to CMS, 2019-2025
28 companies · $1,253 in 2025
The $1,253 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $385 · 2021: $1,002 · 2022: $871 · 2023: $1,289 · 2024: $1,426 · 2025: $1,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,967.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,581.76 | 2022-2025 | |
| Allergan, INC. | $646.33 | 2019-2022 | |
| Glaukos Corporation | $615.03 | 2019-2025 | Idosetr, Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| New World Medical,INC. | $605.58 | 2019-2025 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Alcon Vision LLC | $543.44 | 2020-2025 | Rocklatan, Argos, Tryptyr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $363.52 | 2019-2021 | |
| Nova Eye, INC. | $309.44 | 2024 | |
| Sight Sciences, INC. | $287.30 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Horizon Therapeutics Plc | $274.56 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $267.64 | 2019-2025 | |
| Rxsight INC | $236.65 | 2022-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $188.42 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Johnson & Johnson Surgical Vision, INC. | $173.95 | 2025 | Tecnis Iol |
| Kala Pharmaceuticals, INC. | $155.56 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $140.50 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $132.25 | 2022-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $92.91 | 2020-2023 | |
| Oyster Point Pharma, INC. | $66.48 | 2022-2024 | Tyrvaya, Ryzumvi |
| Ocular Therapeutix, INC. | $47.92 | 2024 | Dextenza |
| Aerie Pharmaceuticals, INC. | $35.87 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $28.76 | 2024 | Xdemvy |
| Rayner Intraocular Lenses Limited | $27.84 | 2025 | Omidria |
| Harrow Eye, LLC | $23.65 | 2025 | |
| Biotissue Holdings INC. | $23.31 | 2025 | |
| Merz Pharmaceuticals, LLC | $23.13 | 2025 | Xeomin |
| Thea Pharma INC. | $19.58 | 2024 | Iyuzeh |
| Shire North American Group INC | $19.30 | 2019 | |
| Iridex Corporation | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gretta Fridman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.